stockrow
Friday 6 November 2026
Export ABVX’s income statement to Excel — free account
Abivax SA Sponsored ADR
ABVX Healthcare Biotechnology
- EPS
- −98.8%
- Free cash flow
- −48.3%
- Total debt
- −98.5%
Quarter to June 2026, against a year earlier
86.16
1.98
+2.35%
Follow ABVX
Alert me
Abivax SA Sponsored ADR (ABVX) P/E ratio
Abivax SA Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SYRE Spyre Therapeutics, Inc. compare | n/m |
| ABVX Abivax SA Sponsored ADR | n/m |
| PRAX Praxis Precision Medicines, Inc. compare | n/m |
| CYTK Cytokinetics, Incorporated compare | n/m |
| AXSM Axsome Therapeutics, Inc. compare | n/m |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | n/m |
| ORKA Oruka Therapeutics, Inc. compare | n/m |
| RYTM Rhythm Pharmaceuticals, Inc. compare | n/m |
| CORT Corcept Therapeutics Incorporated compare | 47.5× |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)